步长制药拟6000万元至1.2亿元回购股份，公司股价年内涨5.50%

Group 1 - The company plans to repurchase shares through centralized bidding, with a total amount between 60 million and 120 million yuan, and a maximum repurchase price of 23.98 yuan per share, which is 45.33% higher than the current price of 16.50 yuan [1] - The company reported a revenue of 8.469 billion yuan for the first nine months of 2025, a decrease of 0.54% year-on-year, while the net profit attributable to shareholders increased by 177.54% to 868 million yuan [2] - The company has distributed a total of 7.948 billion yuan in dividends since its A-share listing, with 1.609 billion yuan distributed in the last three years [3] Group 2 - As of September 30, 2025, the number of shareholders decreased by 7.36% to 51,100, while the average circulating shares per person increased by 2.92% to 20,641 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 8.5127 million shares to 20.3871 million shares, and Southern CSI 500 ETF, which decreased its holdings by 144,500 shares to 8.042 million shares [3]